


<!DOCTYPE html>
<html lang="en">
<head><script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app22.us.archive.org';v.server_ms=597;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>

<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />

<!-- End Wayback Rewrite JS Include -->  

        <title>Management of beta thalassaemia in pregnancy. | National Guideline Clearinghouse</title>

    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width">
    <link rel="icon" href="/web/20180712205104im_/https://www.guideline.gov/UI/images/favicon-NGC.ico">
    <link rel="apple-touch-icon" sizes="180x180" href="/web/20180712205104im_/https://www.guideline.gov/UI/images/apple-touch-icon-NGC.png">
    <link rel="icon" type="image/png" href="/web/20180712205104im_/https://www.guideline.gov/UI/images/favicon-NGC-32x32.png" sizes="32x32">
    <link rel="icon" type="image/png" href="/web/20180712205104im_/https://www.guideline.gov/UI/images/favicon-NGC-16x16.png" sizes="16x16">
    <link rel="manifest" href="/web/20180712205104/https://www.guideline.gov/UI/images/manifest-NGC.json">
    <link rel="mask-icon" href="/web/20180712205104im_/https://www.guideline.gov/UI/images/safari-pinned-tab-NGC.svg" color="#1d4345">
    <meta name="theme-color" content="#ffffff">
    
<link href="/web/20180712205104cs_/https://www.guideline.gov/cassette.axd/stylesheet/8382974d7bae1577062376dcd37102348398fe04/NGCSiteCSS" type="text/css" rel="stylesheet"/>
<!--[if lt IE 9]>
<link href="/cassette.axd/stylesheet/2188ac5b8507764bb4079068f7a3c8d7ccfba0e7/ieCSS" type="text/css" rel="stylesheet"/>
<![endif]-->



    <script async type="text/javascript" id="_fed_an_ua_tag" src="https://web.archive.org/web/20180712205104js_/https://dap.digitalgov.gov/Universal­-Federated-­Analytics-­Min.js?agency=HHS&amp;subagency=AHRQ"></script>
    </head>
<body class="no-js content-page">
<a href="#main-content" id="skip-nav">Skip to main content</a>
<!--https://developers.google.com/tag-manager/devguide#multidomain  ECH-1199-->
    
    <!-- Google Tag Manager -->
    <noscript>
        <iframe src="//web.archive.org/web/20180712205104if_/https://www.googletagmanager.com/ns.html?id=GTM-W4NX5V" height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//web.archive.org/web/20180712205104/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-W4NX5V');</script>

    <noscript>
        <iframe src="//web.archive.org/web/20180712205104if_/https://www.googletagmanager.com/ns.html?id=GTM-KHDP6Z" height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//web.archive.org/web/20180712205104/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-KHDP6Z');</script>
    <!-- End Google Tag Manager -->


    <!-- AHRQ HEADER -->
<div id="ahrq-header">

	<p class="hhs-links">
		<a href="https://web.archive.org/web/20180712205104/http://www.hhs.gov/" target="_blank" class="logo-hhs"><span class="logomark"></span>U.S.&nbsp;Department of&nbsp;Health&nbsp;and Human&nbsp;Services</a>
		<a href="https://web.archive.org/web/20180712205104/http://www.hhs.gov/" target="_blank" class="external-link"><strong>HHS.gov</strong></a>
	</p><!-- /.hhs-links -->
	<p class="ahrq-links">
		<a href="https://web.archive.org/web/20180712205104/http://www.ahrq.gov/" target="_blank" class="logo-ahrq">Agency for Healthcare Research and Quality: Advancing Excellence in Health Care</a>
		<a href="https://web.archive.org/web/20180712205104/http://www.ahrq.gov/" target="_blank" class="external-link"><strong>AHRQ.gov</strong></a>
	</p><!-- /.ahrq-links -->

</div><!-- /#ahrq-header -->

	<!-- HEADER -->
	<div class="header" id="header">
		<div class="masthead">

			<ul class="header-actions">
				<li><a href="#header-search" class="search-action"><span class="label">Search</span></a></li>
				<li><a href="#header-account" class="account-action"><span class="label">Account</span></a></li>
				<li><a href="#main-nav" class="menu-action"><span class="label">Menu</span></a></li>
			</ul><!-- /.header-actions -->
				
				<a href="/web/20180712205104/https://www.guideline.gov/" class="header-logo NGC">
				    <picture>
				        <source media="(min-width: 960px)" srcset="/web/20180712205104im_/https://www.guideline.gov/UI/images/logo_NGC_header.png">
				        <source srcset="/web/20180712205104im_/https://www.guideline.gov/UI/images/logo_NGC_header_m.png">
				        <img src="/web/20180712205104im_/https://www.guideline.gov/UI/images/logo_NGC_header.png" alt="National Guideline Clearinghouse">
				    </picture>
				</a>
<form action="/web/20180712205104/https://www.guideline.gov/search" class="header-search header-action" enctype="multipart/form-data" id="header-search" method="get">					<p class="search-bar">
						<label for="q"><span class="screen-reader-text">Search</span>
							<input id="q" type="text" title="Search Input" name="q" class="search-input" placeholder="Search">
						</label>
						<input id="masthead-search-button" type="submit" title="Search Submit" class="search-submit" value="Search">
					</p>
					<p class="search-tips">
						<a href="/web/20180712205104/https://www.guideline.gov/help-and-about/search-browse/search-tips">Search Tips</a>
					</p>
</form>				<div class="header-account header-action" id="header-account">
				<a id="login-button" class="signin" href="/web/20180712205104/https://www.guideline.gov/accounts/signinlanding" aria-role="tab" aria-controls="login-panel" aria-selected="false">Log into My NGC</a>
<div id="login-panel" class="login dropdown" aria-role="tab-panel" aria-labeledby="login-button" aria-hidden="true">
    
            <div class="sign-in">
            <form id="sign-in-form" action="/web/20180712205104/https://www.guideline.gov/Accounts/LoginSubmit" method="post">
                <h3>Sign In</h3>
                <div class="errormessages"></div>
                <p class="invalid-user-cred message-block" style="display: none;"></p>
                <p>
                    <label for="sign-in-username">Username or Email <span class="required">*</span></label>
                    <input type="text" id="sign-in-username" class="input-text" name="email" required>
                   
                </p>
                <p>
                    <label for="sign-in-userpwd">Password <span class="required">*</span></label>
                    <input type="password" id="sign-in-userpwd" class="input-text" name="password" required>
                  
                </p>
                <p class="form-link"><a href="/web/20180712205104/https://www.guideline.gov/accounts/forgotpassword">Forgot Password?</a></p>
                <p><label for="remember-me"><input type="checkbox" name="remember-me" id="remember-me">Remember Me</label></p>
                <input id="account-sign-in" type="submit" value="Sign In"/>
            </form>
            <p>
                <label for="sign-up-btn">Don't have an account?</label>
                <a href="/web/20180712205104/https://www.guideline.gov/accounts/login" class="sign-up-btn" id="sign-up-btn">Create New Account</a>
            </p>
        </div><!--/.sign-in-->
</div><!-- /.login -->
				</div><!-- /.header-account -->
		</div><!-- /.masthead -->

		<div class="main-nav header-action" id="main-nav">
		    <ul class="level-1">
		        <li class=""><a href="/web/20180712205104/https://www.guideline.gov/">Home</a></li>
		        <li class=""><a href="/web/20180712205104/https://www.guideline.gov/new-this-week/index">New This Week</a></li>
		        <li>
<a href="/web/20180712205104/https://www.guideline.gov/summaries/browse" class="parent-link">Guideline Summaries</a>                    		            <ul class="level-2 dropdown">
                             <li class=""><a href="/web/20180712205104/https://www.guideline.gov/browse/clinical-specialty">By Clinical Specialty</a></li>
		                <li class=""><a href="/web/20180712205104/https://www.guideline.gov/browse/organization">By Organization</a></li>
		                <li class=""><a href="/web/20180712205104/https://www.guideline.gov/browse/mesh-tag">By MeSH Tag</a></li>
		                <li class=""><a href="/web/20180712205104/https://www.guideline.gov/summaries/in-progress">In Progress</a></li>
		                <li class=""><a href="/web/20180712205104/https://www.guideline.gov/summaries/archive">Archive</a></li>

		                <li class=""><a href="/web/20180712205104/https://www.guideline.gov/search?f_DocType=0&amp;fLockTerm=Guideline Summaries">All Summaries</a></li>
		            </ul>
		        </li>
<li class=""><a href="/web/20180712205104/https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li>		        <li class=""><a href="/web/20180712205104/https://www.guideline.gov/expert">Expert Commentaries</a></li>
		        <li class=""><a href="/web/20180712205104/https://www.guideline.gov/matrix">Matrix Tool</a></li>
		        <li class="">
<a href="/web/20180712205104/https://www.guideline.gov/summaries/submit">Submit Guidelines</a>                    		        </li>
                <li class=""><a href="/web/20180712205104/https://www.guideline.gov/help-and-about">Help &amp;&nbsp;About</a></li>		      
		    </ul>
		</div><!-- /.main-nav -->
</div><!-- /.header -->

    <br/><div class="content"><div class="fundingNotice2"><b>The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018</b> because federal funding <br/>through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our <a href="/web/20180712205104/https://www.guideline.gov/home/announcements">full announcement</a>.</div></div>

	<!-- CONTENT -->
	<main id="main-content" tabindex="-1">
		

<div class="main">

		<div class="aside-container">

	<div class="content">

    <!-- CONTENT HEADER -->
    <div class="content-header">
        <ul class="content-header-meta">
            <li class="prefix-icon guideline">Guideline Summary</li>
            <li>NGC:010322</li>
            <li>2014 Mar
            </li>            
                                </ul>
        <div>
                <h1>Management of beta thalassaemia in pregnancy.</h1>
        </div>
    </div>
    <!-- /.content-header-meta -->

        <!-- CONTENT TABS -->
        <ul class="content-tabs">
            <li><a href="#developer-tab" class="developer is-active"><span class="label">Developer</span></a></li>
            <li><a href="#source-tab" class="source"><span class="label">Source</span></a></li>
            <li><a href="#status-tab" class="status"><span class="label">Status</span></a></li>
            <li><a href="#classification-tab" class="classification"><span class="label">Classification</span></a></li>
        </ul>
        <div id="developer-tab" class="is-active content-tab-panel">
                <ul class="developer-list">
        <li><a href="/web/20180712205104/https://www.guideline.gov/search?f_Guideline_Developer_String=Royal%20College%20of%20Obstetricians%20and%20Gynaecologists&amp;fLockTerm=Royal%2BCollege%2Bof%2BObstetricians%2Band%2BGynaecologists">Royal College of Obstetricians and Gynaecologists</a></li>
                        <li>   
                                <a id="833" href="#" data-alert="SignInLanding" data-alert-type="organization" class="get-alerts get-org-alerts">Get Alerts</a>
                        </li>
                </ul>
        </div>
    <!-- /.content-tab-panel -->
    <div id="source-tab" class="content-tab-panel">
<table><tr><td>Royal College of Obstetricians and Gynaecologists (RCOG). Management of beta thalassaemia in pregnancy. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG); 2014 Mar. 17 p.&nbsp;(Green-top guideline; no. 66).&nbsp; [56 references]</td></tr></table>                    <p><a href="/web/20180712205104/https://www.guideline.gov/Home/Disclaimer?id=47919&amp;contentType=fulltextlink&amp;redirect=http%253a%252f%252fwww.rcog.org.uk%252fwomens-health%252fclinical-guidance%252fthalassaemia-pregnancy-management-beta-green-top-guideline-no66">View the original guideline documentation</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712205104im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></p>
    </div>
    <!-- /.content-tab-panel -->
    <div id="status-tab" class="content-tab-panel">
            <p><div class="content_para"><p>This is the current release of the guideline.</p></div></p>
    </div>
    <!-- /.content-tab-panel -->
    <div id="classification-tab" class="content-tab-panel">


        
                    <h4>Age Group</h4>
            <ul>
                        <li><a href="/web/20180712205104/https://www.guideline.gov/search?f_Age_of_Target_Population=Adolescent%20%2813%20to%2018%20years%29&amp;fLockTerm=Adolescent%2B%2813%2Bto%2B18%2Byears%29">Adolescent (13 to 18 years)</a></li>                      
                        <li><a href="/web/20180712205104/https://www.guideline.gov/search?f_Age_of_Target_Population=Adult%20%2819%20to%2044%20years%29&amp;fLockTerm=Adult%2B%2819%2Bto%2B44%2Byears%29">Adult (19 to 44 years)</a></li>                      
            </ul>
                    <h4>UMLS Concepts <a href="/web/20180712205104/https://www.guideline.gov/help-and-about/search-browse/umls-concepts" class="what-is">(what is this?)</a></h4>
                <div class="field">
                    <h5 class="field-label">ICD9CM</h5>
                    <div class="field-content">
<a href="/web/20180712205104/https://www.guideline.gov/search?f_ICD9CM_CUI=C0005283&amp;fLockTerm=Beta+thalassemia">Beta thalassemia</a>
 (282.44)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">MSH</h5>
                    <div class="field-content">
<a href="/web/20180712205104/https://www.guideline.gov/search?f_MSH_CUI=C0282638&amp;fLockTerm=Antibiotic+Prophylaxis">Antibiotic Prophylaxis</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MSH_CUI=C0005058&amp;fLockTerm=Benzoates">Benzoates</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MSH_CUI=C0005283&amp;fLockTerm=beta-Thalassemia">beta-Thalassemia</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MSH_CUI=C0007974&amp;fLockTerm=Chelating+Agents">Chelating Agents</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MSH_CUI=C0007975&amp;fLockTerm=Chelation+Therapy">Chelation Therapy</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MSH_CUI=C0011145&amp;fLockTerm=Deferoxamine">Deferoxamine</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MSH_CUI=C0015915&amp;fLockTerm=Fertilization+in+Vitro">Fertilization in Vitro</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MSH_CUI=C0016410&amp;fLockTerm=Folic+Acid">Folic Acid</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MSH_CUI=C0017382&amp;fLockTerm=Genetic+Counseling">Genetic Counseling</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MSH_CUI=C0206514&amp;fLockTerm=Haemophilus+Vaccines">Haemophilus Vaccines</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MSH_CUI=C0022086&amp;fLockTerm=Iron+Chelating+Agents">Iron Chelating Agents</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MSH_CUI=C0030842&amp;fLockTerm=Penicillins">Penicillins</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MSH_CUI=C0358314&amp;fLockTerm=Pneumococcal+Vaccines">Pneumococcal Vaccines</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MSH_CUI=C0032782&amp;fLockTerm=Postnatal+Care">Postnatal Care</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MSH_CUI=C0085284&amp;fLockTerm=Preconception+Care">Preconception Care</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MSH_CUI=C0032961&amp;fLockTerm=Pregnancy">Pregnancy</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MSH_CUI=C0032964&amp;fLockTerm=Pregnancy+Complications%2c+Hematologic">Pregnancy Complications, Hematologic</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MSH_CUI=C0032972&amp;fLockTerm=Pregnancy+Outcome">Pregnancy Outcome</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MSH_CUI=C0033052&amp;fLockTerm=Prenatal+Care">Prenatal Care</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MSH_CUI=C0034260&amp;fLockTerm=Pyridones">Pyridones</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MSH_CUI=C0455164&amp;fLockTerm=Sperm+Injections%2c+Intracytoplasmic">Sperm Injections, Intracytoplasmic</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MSH_CUI=C0040130&amp;fLockTerm=Thyroid+Function+Tests">Thyroid Function Tests</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MSH_CUI=C0040880&amp;fLockTerm=Triazoles">Triazoles</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">MTH</h5>
                    <div class="field-content">
<a href="/web/20180712205104/https://www.guideline.gov/search?f_MTH_CUI=C0282638&amp;fLockTerm=Antibiotic+Prophylaxis">Antibiotic Prophylaxis</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MTH_CUI=C0005058&amp;fLockTerm=Benzoates">Benzoates</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MTH_CUI=C0005283&amp;fLockTerm=beta+Thalassemia">beta Thalassemia</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MTH_CUI=C0007974&amp;fLockTerm=Chelating+Agents">Chelating Agents</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MTH_CUI=C0002875&amp;fLockTerm=Cooley%27s+anemia">Cooley&#39;s anemia</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MTH_CUI=C0043832&amp;fLockTerm=deferiprone">deferiprone</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MTH_CUI=C0015915&amp;fLockTerm=Fertilization+in+Vitro">Fertilization in Vitro</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MTH_CUI=C0016410&amp;fLockTerm=Folic+Acid">Folic Acid</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MTH_CUI=C0017382&amp;fLockTerm=Genetic+Counseling">Genetic Counseling</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MTH_CUI=C0022086&amp;fLockTerm=Iron+Chelating+Agents">Iron Chelating Agents</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MTH_CUI=C0030842&amp;fLockTerm=Penicillins">Penicillins</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MTH_CUI=C0358314&amp;fLockTerm=Pneumococcal+vaccine">Pneumococcal vaccine</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MTH_CUI=C0032961&amp;fLockTerm=Pregnancy">Pregnancy</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MTH_CUI=C0033052&amp;fLockTerm=Prenatal+care">Prenatal care</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MTH_CUI=C0034260&amp;fLockTerm=Pyridones">Pyridones</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MTH_CUI=C0428530&amp;fLockTerm=Serum+fructosamine+measurement">Serum fructosamine measurement</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_MTH_CUI=C0040130&amp;fLockTerm=Thyroid+Function+Tests">Thyroid Function Tests</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">PDQ</h5>
                    <div class="field-content">
<a href="/web/20180712205104/https://www.guideline.gov/search?f_PDQ_CUI=C1619629&amp;fLockTerm=deferasirox">deferasirox</a>
, <a href="/web/20180712205104/https://www.guideline.gov/search?f_PDQ_CUI=C0016410&amp;fLockTerm=folic+acid">folic acid</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">SNOMEDCT_US</h5>
                    <div class="field-content">
<a href="/web/20180712205104/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0033052&amp;fLockTerm=Antenatal+care">Antenatal care</a>
 (424525001), <a href="/web/20180712205104/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0282638&amp;fLockTerm=Antibiotic+prophylaxis">Antibiotic prophylaxis</a>
 (422181004), <a href="/web/20180712205104/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C2732751&amp;fLockTerm=Assessment+of+risk+of+venous+thromboembolism">Assessment of risk of venous thromboembolism</a>
 (443749004), <a href="/web/20180712205104/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0005283&amp;fLockTerm=beta+Thalassemia">beta Thalassemia</a>
 (65959000), <a href="/web/20180712205104/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0472767&amp;fLockTerm=Beta+thalassemia+intermedia">Beta thalassemia intermedia</a>
 (191189009), <a href="/web/20180712205104/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0419815&amp;fLockTerm=Cardiac+disease+monitoring">Cardiac disease monitoring</a>
 (268509003), <a href="/web/20180712205104/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0022086&amp;fLockTerm=Chelated+iron">Chelated iron</a>
 (95977000), <a href="/web/20180712205104/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0007974&amp;fLockTerm=Chelating+agent">Chelating agent</a>
 (350075001), <a href="/web/20180712205104/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0007974&amp;fLockTerm=Chelating+agent">Chelating agent</a>
 (372627001), <a href="/web/20180712205104/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C1619629&amp;fLockTerm=Deferasirox">Deferasirox</a>
 (417910004), <a href="/web/20180712205104/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C1619629&amp;fLockTerm=Deferasirox">Deferasirox</a>
 (419985007), <a href="/web/20180712205104/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0043832&amp;fLockTerm=Deferiprone">Deferiprone</a>
 (329482000), <a href="/web/20180712205104/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0043832&amp;fLockTerm=Deferiprone">Deferiprone</a>
 (396011004), <a href="/web/20180712205104/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0011145&amp;fLockTerm=Deferoxamine">Deferoxamine</a>
 (372825006), <a href="/web/20180712205104/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0011145&amp;fLockTerm=Deferoxamine">Deferoxamine</a>
 (70702006), <a href="/web/20180712205104/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0455164&amp;fLockTerm=Direct+injection+of+sperm+into+cytoplasm+of+the+oocyte">Direct injection of sperm into cytoplasm of the oocyte</a>
 (225244002), <a href="/web/20180712205104/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0016410&amp;fLockTerm=Folic+acid">Folic acid</a>
 (6247001), <a href="/web/20180712205104/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0016410&amp;fLockTerm=Folic+acid">Folic acid</a>
 (63718003), <a href="/web/20180712205104/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0017382&amp;fLockTerm=Genetic+counseling">Genetic counseling</a>
 (79841006), <a href="/web/20180712205104/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0002875&amp;fLockTerm=Homozygous+beta+thalassemia">Homozygous beta thalassemia</a>
 (26682008), <a href="/web/20180712205104/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0002875&amp;fLockTerm=Homozygous+beta+thalassemia">Homozygous beta thalassemia</a>
 (75451007), <a href="/web/20180712205104/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0015915&amp;fLockTerm=In+vitro+fertilization">In vitro fertilization</a>
 (52637005), <a href="/web/20180712205104/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0030842&amp;fLockTerm=Penicillin+-class+of+antibiotic-">Penicillin -class of antibiotic-</a>
 (373270004), <a href="/web/20180712205104/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0030842&amp;fLockTerm=Penicillin+-class+of+antibiotic-">Penicillin -class of antibiotic-</a>
 (6369005), <a href="/web/20180712205104/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0358314&amp;fLockTerm=Pneumococcal+vaccine">Pneumococcal vaccine</a>
 (333598008), <a href="/web/20180712205104/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0358314&amp;fLockTerm=Pneumococcal+vaccine">Pneumococcal vaccine</a>
 (398730001), <a href="/web/20180712205104/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0032782&amp;fLockTerm=Postpartum+care">Postpartum care</a>
 (133906008), <a href="/web/20180712205104/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0085284&amp;fLockTerm=Preconception+care">Preconception care</a>
 (429070000), <a href="/web/20180712205104/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0032961&amp;fLockTerm=Pregnancy">Pregnancy</a>
 (289908002), <a href="/web/20180712205104/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0428530&amp;fLockTerm=Serum+fructosamine+measurement">Serum fructosamine measurement</a>
 (270997002), <a href="/web/20180712205104/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0040130&amp;fLockTerm=Thyroid+panel">Thyroid panel</a>
 (35650009), <a href="/web/20180712205104/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0040880&amp;fLockTerm=Triazole">Triazole</a>
 (426233002)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
    </div>
        <!-- /.content-tab-panel -->
        <!-- /.content-tab-panel -->
        <!-- TOOLBAR -->
        <div class="content-toolbar">

            <!-- Primary -->
            <ul class="tools primary-tools">
                <li class="dropdown tool sections">
                    <a href="#" class="tool-button">Sections</a>
                    <div class="dropdown-panel">
                            <ul class="section-links">
                                    <li><a href="#420" class="section-mark">Recommendations</a></li>
                                    <li><a href="#396" class="section-mark">Scope</a></li>
                                    <li><a href="#405" class="section-mark">Methodology</a></li>
                                    <li><a href="#424" class="section-mark">Evidence Supporting the Recommendations</a></li>
                                    <li><a href="#427" class="section-mark">Benefits/Harms of Implementing the Guideline Recommendations</a></li>
                                    <li><a href="#430" class="section-mark">Contraindications</a></li>
                                    <li><a href="#432" class="section-mark">Qualifying Statements</a></li>
                                    <li><a href="#434" class="section-mark">Implementation of the Guideline</a></li>
                                    <li><a href="#439" class="section-mark">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></li>
                                    <li><a href="#442" class="section-mark">Identifying Information and Availability</a></li>
                                    <li><a href="#99999" class="section-mark">Disclaimer</a></li>
                            </ul>    
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
            </ul>

            <!-- Other -->
            <ul class="tools other-tools">
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Download</a>

                    <div class="dropdown-panel">
                        <ul>
                            <li><a href="/web/20180712205104/https://www.guideline.gov/summaries/downloadcontent/ngc-10322?contentType=pdf" class="pdf">.PDF 100.0 kb</a></li>
                            <li><a href="/web/20180712205104/https://www.guideline.gov/summaries/downloadcontent/ngc-10322?contentType=word" class="word">Word Document 293.8 kb</a></li>
                            <li><a href="/web/20180712205104/https://www.guideline.gov/summaries/downloadcontent/ngc-10322?contentType=xml" class="xml">.XML 41.5 kb</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Share</a>
                    <div class="dropdown-panel">
                        <ul class="toolbar-social">
                            <li><a target="_blank" href="https://web.archive.org/web/20180712205104/https://www.facebook.com/sharer/sharer.php?u=https://www.guideline.gov/summaries/summary/47919/management-of-beta-thalassaemia-in-pregnancy" class="facebook">Facebook</a></li>
                            <li><a target="_blank" href="https://web.archive.org/web/20180712205104/https://twitter.com/share?text=&amp;url=https://www.guideline.gov/summaries/summary/47919/management-of-beta-thalassaemia-in-pregnancy" class="twitter">Twitter</a></li>
                            <li><a target="_blank" href="https://web.archive.org/web/20180712205104/https://www.linkedin.com/shareArticle?mini=true&amp;url=https://www.guideline.gov/summaries/summary/47919/management-of-beta-thalassaemia-in-pregnancy&amp;title=&amp;summary=&amp;source=" class="linkedin">Linkedin</a></li>
                            <li><a href="https://web.archive.org/web/20180712205104/mailto:/?Subject=AHRQ: Management of beta thalassaemia in pregnancy.&amp;body=https://www.guideline.gov/summaries/summary/47919/management-of-beta-thalassaemia-in-pregnancy" class="email">Email</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Cite</a>
                    <div class="dropdown-panel citation">
                        <p class="text-label"><label for="citation">Citation: </label></p>
                        <textarea id="citation">National Guideline Clearinghouse (NGC). Guideline summary: Management of beta thalassaemia in pregnancy. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2014 Mar 01. [cited 2018 Jul 12]. Available: https://www.guideline.gov</textarea>                        
                        <p class="text-label">Download citation file: </p>
                        <ul>
                            <li><a href="/web/20180712205104/https://www.guideline.gov/summaries/citedownload/47919?format=ris">RIS (Zotero)</a></li>
                            <li><a href="/web/20180712205104/https://www.guideline.gov/summaries/citedownload/47919?format=enw">EndNote</a></li>
                            <li><a href="/web/20180712205104/https://www.guideline.gov/summaries/citedownload/47919?format=bibtex">BibTex</a></li>
                            <li><a href="/web/20180712205104/https://www.guideline.gov/summaries/citedownload/47919?format=txt">Medlars</a></li>
                            <li><a href="/web/20180712205104/https://www.guideline.gov/summaries/citedownload/47919?format=ris">ProCite</a></li>
                            <li><a href="/web/20180712205104/https://www.guideline.gov/summaries/citedownload/47919">RefWorks</a></li>
                            <li><a href="/web/20180712205104/https://www.guideline.gov/summaries/citedownload/47919?format=ris">Reference Manager</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                                
                <li class="tool">
                        <a href="#" id="47919" data-alert="SignInLanding" class="tool-button save-link">Save</a>
                </li>
            </ul>

            <!-- Accordion -->
            <ul class="tools accordion-controls">
                <li class="tool"><a href="#" class="expand-all is-disabled" aria-disabled="true"><span class="screen-reader-text">Expand All</span></a></li>
                <li class="tool"><a href="#" class="collapse-all" aria-disabled="false"><span class="screen-reader-text">Collapse All</span></a></li>
            </ul>
        </div>
        <!-- /.toolbar -->


		<!-- ARTICLE -->
		<div class="article" id="article">
			




    <!-- ACCORDION -->
    <div class="accordion-container" role="tablist" multiselectable="true">
                <h2 id="420" class="accordion-title section-420 is-active" role="tab" aria-expanded="true"><a href="#">Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Major Recommendations</a></h3>
                    <p><div class="content_para"><p><em>In addition to these evidence-based recommendations, the guideline development group also identifies points of best clinical practice in the original guideline document.</em></p>
<p>Classification of evidence levels (<strong>1++ to 4</strong>) and grades of recommendations (<strong>A-D</strong>) are defined at the end of the "Major Recommendations" field.</p>
<p><strong><span style="text-decoration: underline;">Preconception Care</span></strong></p>
<p><strong>What Is the Optimum Preconceptual Care for Women with Thalassaemia?</strong></p>
<p><strong>D</strong> - At each visit with the thalassaemia team, there should be a discussion and documentation of intentions regarding pregnancy. This should include screening for end-organ damage and optimisation of complications prior to embarking on any pregnancy.</p>
<p><strong>Are There Any Interventions Which Are Beneficial at the Preconceptual Stage?</strong></p>
<p><strong>B</strong> - Aggressive chelation in the preconception stage can reduce and optimise body iron burden and reduce end-organ damage.</p>
<p><em>Pancreas</em></p>
<p><strong>D</strong> - Women with established diabetes mellitus should ideally have serum fructosamine concentrations &lt;300 nmol/l for at least 3 months prior to conception. This is equivalent to a glycated haemoglobin (HbA1c) of 43 mmol/mol.</p>
<p><em>Thyroid</em></p>
<p><strong>B</strong> - Thyroid function should be determined. The woman should be euthyroid prepregnancy.</p>
<p><strong>What Medications Should be Reviewed Preconceptually?</strong></p>
<p><strong>D</strong> - Iron chelators should be reviewed and deferasirox and deferiprone ideally discontinued 3 months before conception.</p>
<p><strong>What Is the Importance of Genetic Screening and What Procedure(s) Are Involved for Women with Thalassaemia?</strong></p>
<p><strong>D</strong> - If the partner is a carrier of a haemoglobinopathy that may adversely interact with the woman's genotype then genetic counselling should be offered.</p>
<p><strong>D</strong> - In vitro fertilisation/intracytoplasmic sperm injection (IVF/ICSI) with a pre-implantation genetic diagnosis (PGD) should be considered in the presence of haemoglobinopathies in both partners so that a homozygous or compound heterozygous pregnancy can be avoided.</p>
<p><strong>What Is the Importance of Immunisation and Antibiotic Prophylaxis in Women Who Are at Risk of Transfusion-Related Viral Infections or Have Had a Previous Splenectomy?</strong></p>
<p><strong>C</strong> - All women who have undergone a splenectomy should take penicillin prophylaxis or equivalent.</p>
<p><strong>C</strong> - All women who have undergone a splenectomy should be vaccinated for pneumococcus and <em>Haemophilus influenzae</em> type b if this has not been done before.</p>
<p><strong>What Vitamin Supplements Should Be Recommended?</strong></p>
<p><strong>A</strong> - Folic acid (5 mg) is recommended preconceptually to all women to prevent neural tube defects.</p>
<p><span style="text-decoration: underline;"><strong>Antenatal Care</strong></span></p>
<p><strong>What Is the Optimum Antenatal Management of Iron Chelation Therapy?</strong></p>
<p><em>Management of Women with Myocardial Iron</em></p>
<p><strong>C</strong> - Women with myocardial iron loading should undergo regular cardiology review with careful monitoring of ejection fraction during the pregnancy as signs of cardiac decompensation are the primary indications for intervention with chelation therapy.</p>
<p><strong>C</strong> - Those women at highest risk of cardiac decompensation should commence low-dose subcutaneous desferrioxamine (20 mg/kg/day) on a minimum of 4 to 5 days a week under joint haematology and cardiology guidance from 20 to 24 weeks of gestation.</p>
<p><strong><span style="text-decoration: underline;">Intrapartum Care</span></strong></p>
<p><strong>What Is the Best Intrapartum Management for Women with Thalassaemia Major or Intermedia?</strong></p>
<p><strong>A</strong> - Active management of the third stage of labour is recommended to minimise blood loss.</p>
<p><strong><span style="text-decoration: underline;">Postpartum Care</span></strong></p>
<p><strong>What Should Be the Optimum Care Post Delivery?</strong></p>
<p><strong>D</strong> - Women with thalassaemia should be considered at high risk for venous thromboembolism.</p>
<p><span style="text-decoration: underline;"><strong>Definitions</strong></span>:</p>
<p><strong>Classification of Evidence Levels</strong></p>
<p><strong>1++</strong> High-quality meta-analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a very low risk of bias</p>
<p><strong>1+</strong> Well-conducted meta-analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a low risk of bias</p>
<p><strong>1&ndash;</strong> Meta-analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a high risk of bias</p>
<p><strong>2++</strong> High-quality systematic reviews of case&ndash;control or cohort studies or high quality case&ndash;control or cohort studies with a very low risk of confounding, bias or chance and a high probability that the relationship is causal</p>
<p><strong>2+</strong> Well-conducted case&ndash;control or cohort studies with a low risk of confounding, bias or chance and a moderate probability that the relationship is causal</p>
<p><strong>2&ndash;</strong> Case&ndash;control or cohort studies with a high risk of confounding, bias or chance and a significant risk that the relationship is not causal</p>
<p><strong>3</strong> Non-analytical studies, e.g., case reports, case series</p>
<p><strong>4</strong> Expert opinion</p>
<p><strong>Grades of Recommendations</strong></p>
<p><strong>A</strong> - At least one meta-analysis, systematic review or randomised controlled trial rated as 1++ and <br/>
directly applicable to the target population; or</p>
<p>A systematic review of randomised controlled trials or a body of evidence consisting principally of studies rated as 1+ directly applicable to the target population and demonstrating overall consistency of results</p>
<p><strong>B</strong> - A body of evidence including studies rated as 2++ directly applicable to the target population, and demonstrating overall consistency of results; or</p>
<p>Extrapolated evidence from studies rated as 1++ or 1+</p>
<p><strong>C</strong> - A body of evidence including studies rated as 2+ directly applicable to the target population and demonstrating overall consistency of results; or</p>
<p>Extrapolated evidence from studies rated as 2++</p>
<p><strong>D</strong> - Evidence level 3 or 4; or</p>
<p>Extrapolated evidence from studies rated as 2+</p></div></p>
                        <h3><a href="#">Clinical Algorithm(s)</a></h3>
                    <p><div class="content_para"><p>None provided</p></div></p>

            </div>
                <h2 id="396" class="accordion-title section-396 is-active" role="tab" aria-expanded="true"><a href="#">Scope</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Disease/Condition(s)</a></h3>
                    <p><div class="content_para"><p>Beta (&beta;) thalassaemia major and intermedia in pregnancy</p></div></p>
                        <h3><a href="#">Guideline Category</a></h3>
                    <p>Counseling</p>
                    <p>Evaluation</p>
                    <p>Management</p>
                    <p>Prevention</p>
                    <p>Risk Assessment</p>
                    <p>Treatment</p>
                        <h3><a href="#">Clinical Specialty</a></h3>
                    <p>Hematology</p>
                    <p>Obstetrics and Gynecology</p>
                        <h3><a href="#">Intended Users</a></h3>
                    <p>Advanced Practice Nurses</p>
                    <p>Nurses</p>
                    <p>Physician Assistants</p>
                    <p>Physicians</p>
                        <h3><a href="#">Guideline Objective(s)</a></h3>
                    <p><div class="content_para"><p>To produce evidence-based guidance on the management of women with beta (&beta;) thalassaemia major and intermedia in pregnancy</p></div></p>
                        <h3><a href="#">Target Population</a></h3>
                    <p><div class="content_para"><p>Women with beta (&beta;) thalassaemia major and intermedia in pregnancy (including preconceptual, antenatal, intrapartum and postnatal management and contraception in both primary and secondary care setting)</p></div></p>
                        <h3><a href="#">Interventions and Practices Considered</a></h3>
                    <p><div class="content_para"><p><strong>Preconception Care</strong></p>
<ol style="list-style-type: decimal;" start="1">
    <li>Discussion and documentation of intentions regarding pregnancy
    <ul style="list-style-type: disc;">
        <li>Screening for end-organ damage </li>
        <li>Optimisation of complications prior to pregnancy </li>
    </ul>
    </li>
    <li>Aggressive chelation </li>
    <li>Assessment of serum fructosamine concentrations </li>
    <li>Determination of thyroid function </li>
    <li>Review of iron chelators </li>
    <li>Discontinuation of deferasirox and deferiprone </li>
    <li>Genetic counselling if indicated </li>
    <li>In vitro fertilisation/intracytoplasmic sperm injection (IVF/ICSI) with pre-implantation genetic diagnosis (PGD) if indicated </li>
    <li>Management of women at risk of transfusion-related viral infections or with previous splenectomy
    <ul style="list-style-type: disc;">
        <li>Penicillin prophylaxis or equivalent </li>
        <li>Vaccination for pneumococcus and <em>Haemophilus influenzae</em> type b </li>
    </ul>
    </li>
    <li>Folic acid supplementation </li>
</ol>
<p><strong>Antenatal Care</strong></p>
<p>Management of women with myocardial iron loading</p>
<ul style="list-style-type: disc;">
    <li>Regular cardiology review and monitoring </li>
    <li>Low-dose subcutaneous desferrioxamine </li>
</ul>
<p><strong>Intrapartum Care</strong></p>
<p>Active management of the third stage of labour</p>
<p><strong>Postpartum Care</strong></p>
<p>Consideration of high venous thromboembolism risk</p></div></p>
                        <h3><a href="#">Major Outcomes Considered</a></h3>
                    <p><ul style="list-style-type: disc;">
    <li>Cardiomyopathy in the mother </li>
    <li>Fetal growth restriction </li>
    <li>New endocrinopathies: in particular, diabetes mellitus, hypothyroidism and hypoparathyroidism </li>
    <li>Fertility </li>
    <li>End-organ damage </li>
    <li>Teratogeny </li>
    <li>Breastfeeding </li>
    <li>Haemoglobinopathies and in vitro fertilisation/intracytoplasmic sperm injection </li>
    <li>Pneumococcus and <em>Haemophilus influenzae</em> type b </li>
    <li>Neural tube defects </li>
    <li>Myocardial iron loading </li>
    <li>Venous thromboembolism </li>
</ul></p>

            </div>
                <h2 id="405" class="accordion-title section-405 is-active" role="tab" aria-expanded="true"><a href="#">Methodology</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Methods Used to Collect/Select the Evidence</a></h3>
                    <p>Searches of Electronic Databases</p>
                        <h3><a href="#">Description of Methods Used to Collect/Select the Evidence</a></h3>
                    <p><div class="content_para"><p>This guideline was developed in accordance with standard methodology for producing The Royal College of Obstetricians and Gynaecologists (RCOG) Green-top Guidelines. Databases searched included the Cochrane Database of Systematic Reviews, DARE, EMBASE, TRIP, MEDLINE and PubMed. Search terms included: 'beta thalassaemia', 'Cooley's anaemia', 'Mediterranean anaemia', 'hypogonadotrophic hypogonadism', ovulation induction', 'assisted reproduction', 'iron burden', 'serum ferritin', 'penicillin prophylaxis', 'iron chelation', 'fetal growth and measurement' and 'ultrasonography'. The&nbsp;search was limited to humans and the English language and from 1980 to July 2013. Exclusions were alpha thalassaemia or beta thalassaemia minor. There are no systematic reviews in this area and only small numbers of randomised controlled trials looking at particular interventions. The National Guideline Clearinghouse (NGC) was also searched for relevant guidelines and reviews. Where possible, recommendations are based on available evidence.&nbsp;Areas lacking evidence were highlighted and annotated as 'good practice points.'</p></div></p>
                        <h3><a href="#">Number of Source Documents</a></h3>
                    <p><div class="content_para"><p>Not stated</p></div></p>
                        <h3><a href="#">Methods Used to Assess the Quality and Strength of the Evidence</a></h3>
                    <p>Weighting According to a Rating Scheme (Scheme Given)</p>
                        <h3><a href="#">Rating Scheme for the Strength of the Evidence</a></h3>
                    <p><div class="content_para"><p><strong>Classification of Evidence Levels</strong></p>
<p><strong>1++</strong> High-quality meta-analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a very low risk of bias</p>
<p><strong>1+</strong> Well-conducted meta-analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a low risk of bias</p>
<p><strong>1&ndash;</strong> Meta-analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a high risk of bias</p>
<p><strong>2++</strong> High-quality systematic reviews of case&ndash;control or cohort studies or high quality case&ndash;control or cohort studies with a very low risk of confounding, bias or chance and a high probability that the relationship is causal</p>
<p><strong>2+</strong> Well-conducted case&ndash;control or cohort studies with a low risk of confounding, bias or chance and a moderate probability that the relationship is causal</p>
<p><strong>2&ndash;</strong> Case&ndash;control or cohort studies with a high risk of confounding, bias or chance and a significant risk that the relationship is not causal</p>
<p><strong>3</strong> Non-analytical studies, e.g., case reports, case series</p>
<p><strong>4</strong> Expert opinion</p></div></p>
                        <h3><a href="#">Methods Used to Analyze the Evidence</a></h3>
                    <p>Systematic Review</p>
                        <h3><a href="#">Description of the Methods Used to Analyze the Evidence</a></h3>
                    <p><div class="content_para"><p><strong>Reviewing and Grading of Evidence</strong></p>
<p>Once the evidence has been collated for each clinical question it needs to be appraised and reviewed (refer to section 3 in "Development of RCOG Green-top guidelines: producing a clinical practice guideline" for information on the formulation of the clinical questions; see the "Availability of Companion Documents" field). For each question, the study type with least chance of bias should be used. If available, randomised controlled trials (RCTs) of suitable size and quality should be used in preference to observational data. This may vary depending on the outcome being examined.</p>
<p>The level of evidence and the grade of the recommendations used in this guideline originate from the guidance by the Scottish Intercollegiate Guidelines Network (SIGN) Grading Review Group, which incorporates formal assessment of the methodological quality, quantity, consistency, and applicability of the evidence base. The methods used to appraise individual study types are available from the SIGN Web site (<a href="/web/20180712205104/https://www.guideline.gov/Home/Disclaimer?id=47919&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.sign.ac.uk%2fmethodology%2fchecklists.html" title="SIGN Web site">www.sign.ac.uk/methodology/checklists.html </a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712205104im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>). An objective appraisal of study quality is essential, but paired reviewing by guideline leads may be impractical because of resource constraints.</p>
<p>Once evidence has been collated and appraised, it can be graded. A judgement on the quality of the evidence will be necessary using the grading system (see the "Rating Scheme for the Strength of the Evidence" field). Where evidence is felt to warrant 'down-grading', for whatever reason, the rationale must be stated. Evidence judged to be of poor quality can be excluded. Any study with a high chance of bias (either 1&ndash; or 2&ndash;) will be excluded from the guideline and recommendations will not be based on this evidence. This prevents recommendations being based on poor-quality RCTs when higher-quality observational evidence is available.</p></div></p>
                        <h3><a href="#">Methods Used to Formulate the Recommendations</a></h3>
                    <p>Expert Consensus</p>
                    <p>Informal Consensus</p>
                        <h3><a href="#">Description of Methods Used to Formulate the Recommendations</a></h3>
                    <p><div class="content_para"><p><strong>Guideline Development</strong></p>
<p>The development of guidelines involves more than the collation and reviewing of evidence. Even with high-quality data from systematic reviews of randomised controlled trials, a value judgement is needed when comparing one therapy with another. This will therefore introduce the need for consensus.</p>
<p>The Royal College of Obstetricians and Gynaecologists (RCOG) Green-top Guidelines are drafted by nominated developers, in contrast to other guideline groups such as the National Institute for Health and Care Excellence (NICE) and the Scottish Intercollegiate Guidelines Network (SIGN), who use larger guideline development groups. Equally, in contrast to other guideline groups, the topics chosen for development as Green-top Guidelines are concise enough to allow development by a smaller group of individuals.</p>
<p>In agreeing the precise wording of evidence-based guideline recommendations and in developing consensus-based 'good practice points', the Guidelines Committee will employ an informal consensus approach through group discussion. In line with current methodologies, the entire development process will follow strict guidance and be both transparent and robust. The RCOG acknowledges that formal consensus methods have been described but these require further evaluation in the context of clinical guideline development. It is envisaged that this will not detract from the rigor of the process but prevent undue delays in development.</p></div></p>
                        <h3><a href="#">Rating Scheme for the Strength of the Recommendations</a></h3>
                    <p><div class="content_para"><p><strong>Grades of Recommendations</strong></p>
<p><strong>A</strong> - At least one meta-analysis, systematic review or randomised controlled trial rated as 1++ and directly applicable to the target population; or</p>
<p>A systematic review of randomised controlled trials or a body of evidence consisting principally of studies rated as 1+ directly applicable to the target population and demonstrating overall consistency of results</p>
<p><strong>B</strong> - A body of evidence including studies rated as 2++ directly applicable to the target population, and demonstrating overall consistency of results; or</p>
<p>Extrapolated evidence from studies rated as 1++ or 1+</p>
<p><strong>C</strong> - A body of evidence including studies rated as 2+ directly applicable to the target population and demonstrating overall consistency of results; or</p>
<p>Extrapolated evidence from studies rated as 2++</p>
<p><strong>D</strong>&nbsp;- Evidence level 3 or 4; or</p>
<p>Extrapolated evidence from studies rated as 2+</p></div></p>
                        <h3><a href="#">Cost Analysis</a></h3>
                    <p><div class="content_para"><p>A formal cost analysis was not performed and published cost analysis were not reviewed.</p></div></p>
                        <h3><a href="#">Method of Guideline Validation</a></h3>
                    <p>External Peer Review</p>
                    <p>Internal Peer Review</p>
                        <h3><a href="#">Description of Method of Guideline Validation</a></h3>
                    <p><div class="content_para"><p>Following discussion in the Guidelines Committee (GC), each Green-top guideline is formally peer reviewed. At the same time, the draft guideline is published on the Royal College of Obstetricians and Gynaecologists (RCOG) Web site for further peer discussion before final publication.</p>
<p>All comments will be collated by the RCOG and tabulated for consideration by the guideline leads. Each comment will require discussion. Where comments are rejected then justification will need to be made. Following this review, the document will be updated and the GC will then review the revised draft and the table of comments.</p>
<p>Once the GC signs-off on the guideline, it is submitted to the Clinical Quality Board for approval before final publication.</p></div></p>

            </div>
                <h2 id="424" class="accordion-title section-424 is-active" role="tab" aria-expanded="true"><a href="#">Evidence Supporting the Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Type of Evidence Supporting the Recommendations</a></h3>
                    <p><div class="content_para"><p>The type of supporting evidence is identified and graded for each recommendation (see the "Major Recommendations" field).</p></div></p>

            </div>
                <h2 id="427" class="accordion-title section-427 is-active" role="tab" aria-expanded="true"><a href="#">Benefits/Harms of Implementing the Guideline Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Potential Benefits</a></h3>
                    <p><div class="content_para"><p>Appropriate preconceptual, antenatal, intrapartum and postnatal management and contraception in women with beta (&beta;) thalassaemia major and intermedia in pregnancy in both primary and secondary care settings</p></div></p>
                        <h3><a href="#">Potential Harms</a></h3>
                    <p><ul style="list-style-type: disc;">
    <li>Fertility may be reduced in transfusion-dependent individuals where chelation has been suboptimal and iron overload has occurred resulting in damage to the anterior pituitary. </li>
    <li>Due to lack of safety data, all chelation therapy should be regarded as potentially teratogenic in the first trimester. Desferrioxamine is the only chelation agent with a body of evidence for use in the second and third trimester but should be avoided in the first trimester owing to lack of safety data. The optimisation of iron burden is therefore critical as the ongoing iron accumulation from transfusion in the absence of chelation may expose the pregnant woman to a high risk of new complications related to iron overload, particularly diabetes and cardiomyopathy. </li>
    <li>Women who are transfused regularly or intermittently are at risk of transfusion-transmitted infections. It is therefore important to ascertain infectivity and manage the common transfusion related viral infections appropriately. </li>
    <li>Women with thalassaemia major and myocardial iron loading with T2* of &lt;10 ms are at high risk of cardiac decompensation which may present as increasing breathlessness, paroxysmal nocturnal dyspnoea, orthopnoea, syncope, palpitations or peripheral oedema. Presentation in the first trimester is associated with adverse clinical outcome. </li>
</ul></p>

            </div>
                <h2 id="430" class="accordion-title section-430 is-active" role="tab" aria-expanded="true"><a href="#">Contraindications</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Contraindications</a></h3>
                    <p><ul style="list-style-type: disc;">
    <li>All bisphosphonates are contraindicated in pregnancy and should ideally be discontinued 3 months prior to conception in accordance with the product safety information sheet </li>
    <li>A reduced ejection fraction is a relative contraindication to pregnancy and the management should be the subject of multidisciplinary discussions involving a cardiologist with experience of cardiac pathology in pregnancy, a maternal medicine specialist, a haematologist and an obstetric anaesthetist </li>
</ul></p>

            </div>
                <h2 id="432" class="accordion-title section-432 is-active" role="tab" aria-expanded="true"><a href="#">Qualifying Statements</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Qualifying Statements</a></h3>
                    <p><ul style="list-style-type: disc;">
    <li>The Royal College of Obstetricians and Gynaecologists (RCOG)&nbsp;produces guidelines as an educational aid to good clinical practice. They present recognised methods and techniques of clinical practice, based on published evidence, for consideration by obstetricians and gynaecologists and other relevant health professionals. The ultimate judgement regarding a particular clinical procedure or treatment plan must be made by the doctor or other attendant in the light of clinical data presented by the patient and the diagnostic and treatment options available within the appropriate health services. This means that RCOG Guidelines are unlike protocols or guidelines issued by employers, as they are not intended to be prescriptive directions defining a single course of management. Departure from the local prescriptive protocols or guidelines should be fully documented in the patient's case notes at the time the relevant decision is taken. </li>
    <li>These recommendations are not intended to dictate an exclusive course of management or treatment. They must be evaluated with reference to individual patient needs, resources and limitations unique to the institution and variations in local populations. It is hoped that this process of local ownership will help to incorporate these guidelines into routine practice. Attention is drawn to areas of clinical uncertainty where further research might be indicated. </li>
</ul></p>

            </div>
                <h2 id="434" class="accordion-title section-434 is-active" role="tab" aria-expanded="true"><a href="#">Implementation of the Guideline</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Description of Implementation Strategy</a></h3>
                    <p><div class="content_para"><p>An implementation strategy was not provided.</p></div></p>
                        <h3><a href="#">Implementation Tools</a></h3>
                    <p>Audit Criteria/Indicators</p>
                    <p>Mobile Device Resources</p>
                    <p><div class="general-block">For information about availability, see the <i>Availability of Companion Documents</i> and <i>Patient Resources</i> fields below.</div></p>

            </div>
                <h2 id="439" class="accordion-title section-439 is-active" role="tab" aria-expanded="true"><a href="#">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">IOM Care Need</a></h3>
                    <p>Living with Illness</p>
                    <p>Staying Healthy</p>
                        <h3><a href="#">IOM Domain</a></h3>
                    <p>Effectiveness</p>
                    <p>Safety</p>

            </div>
                <h2 id="442" class="accordion-title section-442 is-active" role="tab" aria-expanded="true"><a href="#">Identifying Information and Availability</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Bibliographic Source(s)</a></h3>
                    <p><table><tr><td>Royal College of Obstetricians and Gynaecologists (RCOG). Management of beta thalassaemia in pregnancy. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG); 2014 Mar. 17 p.&nbsp;(Green-top guideline; no. 66).&nbsp; [56 references]</td></tr></table></p>
                        <h3><a href="#">Adaptation</a></h3>
                    <p><div class="content_para"><p>Not applicable. The guideline was not adapted from another source.</p></div></p>
                        <h3><a href="#">Date Released</a></h3>
                    <p>2014 Mar</p>
                        <h3><a href="#">Guideline Developer(s)</a></h3>
                    <p>Royal College of Obstetricians and Gynaecologists - Medical Specialty Society</p>
                        <h3><a href="#">Source(s) of Funding</a></h3>
                    <p><div class="content_para"><p>Royal College of Obstetricians and Gynaecologists</p></div></p>
                        <h3><a href="#">Guideline Committee</a></h3>
                    <p><div class="content_para"><p>Guidelines Committee</p></div></p>
                        <h3><a href="#">Composition of Group That Authored the Guideline</a></h3>
                    <p><div class="content_para"><p><em>Authors</em>: Miss AAA Kyei-Mensah FRCOG, London; Mr B Davis FRCP FRCPath MD, London; Dr M Gupta MRCOG, London; Mr G Lieberman MRCOG, London; Ms H Morgan FRCOG, London; Dr FT Shah FRCP FRCPath MD, London</p>
<p><em>Peer Reviewers</em>: Dr C Bagot, Consultant Haematologist, Glasgow; Mrs A Diyaf MRCOG, Barnstaple; Mr DI Fraser FRCOG, Norwich; Professor R Hussain FRCOG, Karachi, Pakistan, on behalf of the Pakistan Representative Committee; Dr S Pavord, Leicester Royal Infirmary, Leicester; RCOG Women's Network; Royal College of General Practitioners; Royal College of Midwives; Ms SM Tuck FRCOG, London; UK National Screening Committee; UK Thalassaemia Society</p>
<p><em>Guideline Committee Lead Reviewers</em>: Dr P Owen FRCOG, Glasgow; Mr M Griffiths FRCOG, Luton</p></div></p>
                        <h3><a href="#">Financial Disclosures/Conflicts of Interest</a></h3>
                    <p><div class="content_para"><p>Conflicts of interest: None declared.</p></div></p>
                        <h3><a href="#">Guideline Status</a></h3>
                    <p><div class="content_para"><p>This is the current release of the guideline.</p></div></p>
                        <h3><a href="#">Guideline Availability</a></h3>
                    <p><div class="content_para"><p>Electronic copies: Available from the <a href="/web/20180712205104/https://www.guideline.gov/Home/Disclaimer?id=47919&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.rcog.org.uk%2fwomens-health%2fclinical-guidance%2fthalassaemia-pregnancy-management-beta-green-top-guideline-no66" title="Royal College of Obstetricians and Gynaecologists (RCOG) Web site">Royal College of Obstetricians and Gynaecologists (RCOG) Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712205104im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>.</p></div></p>
                        <h3><a href="#">Availability of Companion Documents</a></h3>
                    <p><div class="content_para"><p>The following are available:</p>
<ul style="list-style-type: disc;">
    <li>Development of RCOG Green-top guidelines: policies and processes. Clinical Governance Advice No 1a. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG); 2006 Nov. 6 p. Electronic copies: Available from the <a href="/web/20180712205104/https://www.guideline.gov/Home/Disclaimer?id=47919&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.rcog.org.uk%2fgreen-top-development" title="RCOG Web site">Royal College of Obstetricians and Gynaecologists (RCOG) Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712205104im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
    <li>Development of RCOG Green-top guidelines: producing a scope. Clinical Governance Advice No 1b. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG); 2006 Nov. 4 p. Electronic copies: Available from the <a href="/web/20180712205104/https://www.guideline.gov/Home/Disclaimer?id=47919&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.rcog.org.uk%2fwomens-health%2fclinical-guidance%2fdevelopment-rcog-green-top-guidelines-producing-scope" title="RCOG Web site">RCOG Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712205104im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
    <li>Development of RCOG Green-top guidelines: producing a clinical practice guideline. Clinical Governance Advice No 1c. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG); 2006 Nov. 13 p. Electronic copies: Available from the <a href="/web/20180712205104/https://www.guideline.gov/Home/Disclaimer?id=47919&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.rcog.org.uk%2fwomens-health%2fclinical-guidance%2fdevelopment-rcog-green-top-guidelines-producing-clinical-practice-gu" title="RCOG Web site">RCOG Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712205104im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
    <li>Development of RCOG Green-top guidelines: consensus methods for adaptation of Green-top guidelines. Clinical Governance Advice No 1d. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG); 2010 Feb. 9 p. Electronic copies: Available from the <a href="/web/20180712205104/https://www.guideline.gov/Home/Disclaimer?id=47919&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.rcog.org.uk%2fdevelopment-of-rcog-green-top-guidelines-consensus-methods" title="RCOG Web site">RCOG Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712205104im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
</ul>
<p>Suggested audit topics can be found in Section 7 of the <a href="/web/20180712205104/https://www.guideline.gov/Home/Disclaimer?id=47919&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.rcog.org.uk%2ffiles%2frcog-corp%2fGTG_66_Thalassaemia.pdf" title="RCOG Web site">original guideline document</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712205104im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>.</p>
<p>In addition, a mobile app for RCOG Green-top guidelines is available from the <a href="/web/20180712205104/https://www.guideline.gov/Home/Disclaimer?id=47919&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.rcog.org.uk%2frcog-guidelines-app" title="RCOG Web site">RCOG website</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712205104im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>.</p></div></p>
                        <h3><a href="#">Patient Resources</a></h3>
                    <p><div class="content_para"><p>None available</p></div></p>
                        <h3><a href="#">NGC Status</a></h3>
                    <p><div class="content_para"><p>This NGC summary was completed by ECRI Institute on May 15, 2014. The information was verified by the guideline developer on June 3, 2014.</p></div></p>
                        <h3><a href="#">Copyright Statement</a></h3>
                    <p><div class="content_para"><p>This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.</p></div></p>

            </div>
                <h2 id="99999" class="accordion-title section-99999 is-active" role="tab" aria-expanded="true"><a href="#">Disclaimer</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">NGC Disclaimer</a></h3>
                    <p><p>The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the <a href="/web/20180712205104/https://www.guideline.gov/help-and-about/summaries/inclusion-criteria">NGC Inclusion Criteria</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p></p>

            </div>

    </div>
    <!-- /.accordion-container -->

<!-- ASIDE -->
<!-- FOOTER -->






		</div><!-- /.article -->

	</div><!-- /.content -->

	
			<div class="aside">
				

    <!-- About NGC -->
    <div class="info-block">
            <h3 class="info prefix-icon large-icon">About NGC Guideline Summaries</h3>
            <p>NGC provides structured summaries containing information from clinical practice guidelines.</p>
            <ul>
                <li><a href="/web/20180712205104/https://www.guideline.gov/help-and-about/summaries/inclusion-criteria" class="internal-link">Inclusion Criteria</a></li>
                <li><a href="/web/20180712205104/https://www.guideline.gov/help-and-about/summaries/template-of-guideline-attributes" class="internal-link">Template of Guideline Attributes</a></li>
                <li><a href="/web/20180712205104/https://www.guideline.gov/help-and-about/summaries/classification-scheme" class="internal-link">Classification Scheme</a></li>
            </ul>
            <p><a href="/web/20180712205104/https://www.guideline.gov/help-and-about/summaries/faqs" class="help-button">Guideline Summary FAQs</a></p>

    </div>
    <!-- /info-block -->

    <!-- Guideline Synthesis -->

    <!-- HHS Block -->

    <!-- Related Content -->


    <hr>

    <!-- New on NGC -->
    <div class="subscribe-header">
        <h3 class="subscribe-title">New on NGC</h3>
        <ul class="subscribe-links">
            <li><a href="/web/20180712205104/https://www.guideline.gov/subscribe" class="newsletter"><span class="subscribe-links-label">Get Email Alerts</span></a></li>
            <li><a href="/web/20180712205104/https://www.guideline.gov/rssFiles/ngc_newthisweek.xml" class="rss"><span class="subscribe-links-label">RSS Feed</span></a></li>
        </ul>
    </div>
    <!-- /.subscribe-header -->
        <h5 class="prefix-icon guideline news-list-category-label">Guideline Summaries</h5>
        <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011378</li>
            <li>2017 Oct</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712205104/https://www.guideline.gov/summaries/summary/51300/mental-health-care-in-the-perinatal-period-australian-clinical-practice-guideline">Mental health care in the perinatal period: Australian clinical practice guideline.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011372</li>
            <li>2015</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712205104/https://www.guideline.gov/summaries/summary/51294/clinical-practice-guideline-on-systemic-lupus-erythematosus">Clinical practice guideline on systemic lupus erythematosus.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011385</li>
            <li>2018 Mar</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712205104/https://www.guideline.gov/summaries/summary/51326/vadod-clinical-practice-guideline-for-the-management-of-pregnancy">VA/DoD clinical practice guideline for the management of pregnancy.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011376</li>
            <li>2018 Feb</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712205104/https://www.guideline.gov/summaries/summary/51298/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-dihydropyrimidine-dehydrogenase-genotype-and-fluoropyrimidine-dosing-2017-update">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011370</li>
            <li>2017 Dec</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712205104/https://www.guideline.gov/summaries/summary/51292/the-implementation-of-targeted-temperature-management-an-evidencebased-guideline-from-the-neurocritical-care-society">The implementation of targeted temperature management: an evidence-based guideline from the Neurocritical Care Society.</a></p>
    </div>

    <a class="block-link" href="/web/20180712205104/https://www.guideline.gov/new-this-week/index">
        <h3>New This Week </h3>
        <p>View more and sign up for our Newsletter</p>
    </a>
    <!-- Adobe Reader -->
    <p><a href="/web/20180712205104/https://www.guideline.gov/disclaimer?id=47919&amp;contentType=summary&amp;redirect=http%3A%2F%2Fget.adobe.com%2Freader%2F" class="external-link">Get Adobe Reader</a></p>

			</div><!-- /.aside -->
		</div><!-- /.aside-container -->

	<!-- BACK TO TOP -->
	
	
	



    <!-- COMMENTS -->
    

</div><!-- /.main -->

	</main>

	<!-- FOOTER -->
	<div class="footer" id="footer">

		<div class="footer-grid-container">
			<!-- Header -->
			<div class="footer-header">
				<a href="#" class="footer-logo">
			 		<picture>
					  	<source type="image/svg+xml" srcset="/web/20180712205104im_/https://www.guideline.gov/UI/images/logo_NGC_footer.svg">
					  	<img src="/web/20180712205104im_/https://www.guideline.gov/UI/images/logo_NGC_footer.png" alt="NGC">
					</picture>
				</a>
			</div><!-- /.footer-header -->

			<!-- Content -->
			<div class="footer-content">
				<div class="footer-nav">
					<ul class="level-1">
						<li><a href="/web/20180712205104/https://www.guideline.gov/">Home</a></li>
		                <li><a href="/web/20180712205104/https://www.guideline.gov/new-this-week/index">New This Week</a></li>
						<li><a href="/web/20180712205104/https://www.guideline.gov/browse/organization" class="parent-link">Guideline Summaries</a></li>
<li><a href="/web/20180712205104/https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li>						<li><a href="/web/20180712205104/https://www.guideline.gov/expert">Expert Commentaries</a></li>
		                <li><a href="/web/20180712205104/https://www.guideline.gov/matrix">Matrix Tool</a></li>
						<li><a href="/web/20180712205104/https://www.guideline.gov/summaries/submit">Submit Guidelines</a></li>
						<li><a href="/web/20180712205104/https://www.guideline.gov/help-and-about">Help &amp;&nbsp;About</a></li>
					</ul>
					<ul class="level-2">
						<li><a href="/web/20180712205104/https://www.guideline.gov/contact-us">Contact Us</a></li>
						<li><a href="/web/20180712205104/https://www.guideline.gov/rss">RSS</a></li>
					    <li><a href="/web/20180712205104/https://www.guideline.gov/site-map">Site Map</a></li>
                        <li><a href="/web/20180712205104/https://www.guideline.gov/browse/related">Related NQMC Measures</a></li>
                        <li><a href="/web/20180712205104/https://www.guideline.gov/help-and-about/about/editorial-board">Editorial Board</a></li>
                        <li><a href="/web/20180712205104/https://www.guideline.gov/help-and-about/general/web-site-credits">Web Site Credits</a></li>
                        <li><a href="/web/20180712205104/https://www.guideline.gov/help-and-about/general/disclaimer">Disclaimer</a></li>
						<li><a href="/web/20180712205104/https://www.guideline.gov/help-and-about/general/privacy">Privacy Policy</a></li>
                        <li><a href="/web/20180712205104/https://www.guideline.gov/help-and-about/technical/accessibility">Accessibility</a></li>	
                        <li><a href="/web/20180712205104/https://www.guideline.gov/help-and-about/technical/for-web-developers">For Web Developers</a></li>
					</ul>
				</div><!-- /.footer-nav -->
			</div><!-- /.footer-content -->

			<!-- Aside -->
			<div class="footer-aside">
				<h5 class="footer-partner-link-header">Visit our partner sites</h5>
				<ul class="footer-partner-links">
				    <li><!-- NQMC footer link -->
						<a href="https://web.archive.org/web/20180712205104/https://www.qualitymeasures.ahrq.gov/" target="_blank" class="partner-button nqmc">
							<span class="partner-logo">
								<picture>
							    	<source type="image/svg+xml" srcset="/web/20180712205104im_/https://www.guideline.gov/UI/images/logo_footerlink_nqmc.svg">
									<img src="/web/20180712205104im_/https://www.guideline.gov/UI/images/logo_footerlink_nqmc.png" alt="National Quality Measures Clearinghouse"/>
								</picture>
							</span>
						</a>
					</li><!--/MQMC footer Link -->
					<li><!-- HHS footer link --> 
						<a href="https://web.archive.org/web/20180712205104/https://www.qualitymeasures.ahrq.gov/hhs/index.aspx" target="_blank" class="partner-button hhs">
							<span class="partner-logo">
								<picture>
								    <source type="image/svg+xml" srcset="/web/20180712205104im_/https://www.guideline.gov/UI/images/logo_footerlink_hmis.svg">
								    <img src="/web/20180712205104im_/https://www.guideline.gov/UI/images/logo_footerlink_hmis.png" alt="HHS Measures Inventory"/>
								</picture>
							</span>
						</a>
					</li><!--/HHS footer link -->
				</ul>
			</div><!-- /.footer-aside -->

		</div><!-- /.footer-grid-container -->

	</div><!-- /.footer -->

	
	<!-- AHRQ FOOTER -->
	<div id="ahrq-footer">

		<!-- FIRST -->
		<div class="ahrq-first-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<p><a href="https://web.archive.org/web/20180712205104/http://www.ahrq.gov/index.html" class="ahrq-footer-logo" target="_blank">AHRQ</a></p>
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="https://web.archive.org/web/20180712205104/http://www.ahrq.gov/policy/electronic/accessibility/index.html" target="_blank">Accessibility</a></li>
						<li><a href="https://web.archive.org/web/20180712205104/http://www.ahrq.gov/policy/electronic/disclaimers/index.html" target="_blank">Disclaimers</a></li>
						<li><a href="https://web.archive.org/web/20180712205104/http://www.ahrq.gov/policy/eeo/index.html" target="_blank">EEO</a></li>
						<li><a href="https://web.archive.org/web/20180712205104/http://www.ahrq.gov/policy/foia/index.html" target="_blank">FOIA</a></li>
						<li><a href="https://web.archive.org/web/20180712205104/http://www.hhs.gov/web/governance/digital-strategy/index.html" target="_blank">HHS Digital Strategy</a></li>
						<li><a href="https://web.archive.org/web/20180712205104/http://oig.hhs.gov/" target="_blank">Inspector General</a></li>
						<li><a href="https://web.archive.org/web/20180712205104/http://www.ahrq.gov/policy/electronic/plain-writing/index.html" target="_blank">Plain Writing Act</a></li>
						<li><a href="https://web.archive.org/web/20180712205104/http://www.ahrq.gov/policy/electronic/privacy/index.html" target="_blank">Privacy Policy</a></li>
						<li><a href="https://web.archive.org/web/20180712205104/http://www.ahrq.gov/policy/electronic/about/policyix.html" target="_blank">Electronic Policies</a></li>
						<li><a href="https://web.archive.org/web/20180712205104/http://www.hhs.gov/plugins.html" target="_blank">Viewers &amp; Players</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<h3>Get Social</h3>
					<ul class="ahrq-social">
						<li><a href="https://web.archive.org/web/20180712205104/http://www.facebook.com/" target="_blank" class="facebook"><span class="screen-reader-text">Facebook</span></a></li>
						<li><a href="https://web.archive.org/web/20180712205104/http://www.twitter.com/" target="_blank" class="twitter"><span class="screen-reader-text">Twitter</span></a></li>
						<li><a href="https://web.archive.org/web/20180712205104/http://www.linkedin.com/" target="_blank" class="linkedin"><span class="screen-reader-text">LinkedIn</span></a></li>
						<li><a href="https://web.archive.org/web/20180712205104/http://www.youtube.com/" target="_blank" class="youtube"><span class="screen-reader-text">YouTube</span></a></li>
					</ul>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.first-footer -->

		<!-- SECOND -->
		<div class="ahrq-second-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<ul>
						<li><a href="https://web.archive.org/web/20180712205104/http://www.ahrq.gov/index.html" target="_blank" class="ahrq-footer-home-link"><span class="screen-reader-text">AHRQ Home</span></a></li>
						<li><a href="https://web.archive.org/web/20180712205104/http://www.ahrq.gov/cpi/about/index.html" target="_blank">About Us</a></li>
						<li><a href="https://web.archive.org/web/20180712205104/http://www.ahrq.gov/cpi/about/careers/index.html" target="_blank">Careers</a></li>
						<li><a href="https://web.archive.org/web/20180712205104/http://www.ahrq.gov/contact/index.html" target="_blank">Contact Us</a></li>
						<li><a href="https://web.archive.org/web/20180712205104/http://www.ahrq.gov/Sitemap.html" target="_blank">Sitemap</a></li>
						<li><a href="https://web.archive.org/web/20180712205104/https://info.ahrq.gov/" target="_blank">FAQ</a></li>
					</ul>	
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="https://web.archive.org/web/20180712205104/http://www.ahrq.gov/health-care-information/index.html" target="_blank">Health Care Information</a></li>
						<li><a href="https://web.archive.org/web/20180712205104/http://www.ahrq.gov/patients-consumers/index.html" target="_blank">For Patients &amp; Consumers</a></li>
						<li><a href="https://web.archive.org/web/20180712205104/http://www.ahrq.gov/professionals/index.html" target="_blank">For Professionals</a></li>
						<li><a href="https://web.archive.org/web/20180712205104/http://www.ahrq.gov/policymakers/index.html" target="_blank">For Policymakers</a></li>
						<li><a href="https://web.archive.org/web/20180712205104/http://www.ahrq.gov/research/index.html" target="_blank">Research Tools &amp; Data</a></li>
						<li><a href="https://web.archive.org/web/20180712205104/http://www.ahrq.gov/funding/index.html" target="_blank">Funding &amp; Grants</a></li>
						<li><a href="https://web.archive.org/web/20180712205104/http://www.ahrq.gov/cpi/index.html" target="_blank">Offices, Centers &amp; Programs</a></li>
						<li><a href="https://web.archive.org/web/20180712205104/http://www.ahrq.gov/news/index.html" target="_blank">News &amp; Events</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<ul>
						<li><a href="https://web.archive.org/web/20180712205104/http://www.hhs.gov/" target="_blank">U.S. Department of Health &amp; Human Services</a></li>
						<li><a href="https://web.archive.org/web/20180712205104/http://www.whitehouse.gov/" target="_blank">The White House</a></li>
						<li><a href="https://web.archive.org/web/20180712205104/http://www.usa.gov/" target="_blank">USA.gov: The U.S. Government's Official Web Portal   </a></li>
					</ul>
					<p class="ahrq-address">
						<strong>Agency for Healthcare Research&nbsp;and&nbsp;Quality</strong>
					    <br/>5600 Fishers Lane
					    <br/>Rockville, MD 20857
					    <br/><strong>Telephone:</strong> (301) 427-1364
					</p>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.second-footer -->
	</div><!-- /#ahrq-footer -->


	
	<!-- SCRIPTS -->
	
<script src="//web.archive.org/web/20180712205104js_/https://ajax.googleapis.com/ajax/libs/jquery/1.6.3/jquery.min.js" type="text/javascript"></script>
<script type="text/javascript">
if(!window.jQuery){
document.write('<script src="/cassette.axd/script/cdd67f922f9d413eaccb759182297335f87c3ff7/UI/js/jquery.js" type="text/javascript"><\/script>');
}
</script>
<script src="/web/20180712205104js_/https://www.guideline.gov/cassette.axd/script/595952c286b7fd52f0737b6f62085709be93156a/bodyJS" type="text/javascript"></script>

    
</body>
</html>
<!--
     FILE ARCHIVED ON 20:51:04 Jul 12, 2018 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 17:53:23 Jul 15, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 481.058 (3)
  esindex: 0.009
  captures_list: 508.766
  CDXLines.iter: 20.097 (3)
  PetaboxLoader3.datanode: 462.921 (4)
  exclusion.robots: 0.288
  exclusion.robots.policy: 0.269
  RedisCDXSource: 0.886
  load_resource: 52.103
-->